Medical Director, Pediatric Hematology/Oncology
Sarah Cannon Center for Blood Cancer at The Children’s Hospital at TriStar Centennial
Nashville, Tennessee, United States
Haydar Frangoul, MD, MS. is the Director of the Pediatric Stem Cell Transplant program at the Sarah Cannon Research Institute and Tristar Centennial Children's Hospital and in Nashville Tennessee. Dr Frangoul completed his MD degree at the American University of Beirut followed by Pediatric residency at Duke University. He then went to complete a fellowship in Pediatric Hematology/Oncology and Stem Cell Transplant at the University of Washington and the Fred Hutchinson Cancer Center. He was the Carolyn Perot Rathjen Endowed Professor of Pediatric Hematology/Oncology at Vanderbilt University until 2015 when he joined Sarah Cannon Research Institute to lead the Pediatric Stem Cell Transplant Program.
Dr Frangoul had leadership positions in the Children Oncology group, and Pediatric Blood and Marrow Transplant Consortium. His primary interest is allogeneic stem cell transplant using an alternative donor sources especially for non-malignant diseases. Dr Frangoul has authored or co-authored more than 140 peer reviewed manuscripts. He has been an invited speaker at numerous national and international conferences. He is the lead investigator for the clinical trial using CRISPR-Cas9 gene editing for patients with sickle cell disease.
Disclosure information not submitted.
Plenary Session: Curative Options in Sickle Cell Disease: Gene Therapy and Transplant
Saturday, June 8, 2024
3:30 PM – 5:45 PM ET
Saturday, June 8, 2024
3:30 PM – 3:35 PM ET
CRISPR Gene Editing for Sickle Cell Disease
Saturday, June 8, 2024
4:35 PM – 5:05 PM ET